Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002, JMT101, and Enlonstobart in Advanced HNSCC
NCT06989671Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of CRB-701 in head and neck squamous cell carcinoma (HNSCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
CRB-701
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06989671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989671.